CureVac Past Earnings Performance
Past criteria checks 0/6
CureVac's earnings have been declining at an average annual rate of -14.2%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 12.8% per year.
Key information
-14.2%
Earnings growth rate
104.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -12.8% |
| Return on equity | -61.2% |
| Net Margin | -463.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How CureVac makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 59 | -273 | 92 | 119 |
| 31 Dec 23 | 54 | -260 | 96 | 116 |
| 30 Sep 23 | 43 | -302 | 95 | 110 |
| 30 Jun 23 | 38 | -301 | 103 | 95 |
| 31 Mar 23 | 50 | -291 | 106 | 76 |
| 31 Dec 22 | 67 | -249 | 107 | 63 |
| 30 Sep 22 | 97 | -122 | 100 | 566 |
| 30 Jun 22 | 115 | -219 | 103 | 602 |
| 31 Mar 22 | 117 | -313 | 105 | 722 |
| 31 Dec 21 | 103 | -412 | 102 | 816 |
| 30 Sep 21 | 68 | -468 | 102 | 322 |
| 30 Jun 21 | 44 | -361 | 81 | 308 |
| 31 Mar 21 | 56 | -219 | 64 | 208 |
| 31 Dec 20 | 49 | -129 | 54 | 114 |
| 30 Sep 20 | 50 | -107 | 56 | 89 |
| 31 Mar 20 | 17 | -102 | 56 | 43 |
| 31 Dec 19 | 17 | -100 | 51 | 43 |
| 31 Dec 18 | 13 | -71 | 26 | 42 |
Quality Earnings: 5CV is currently unprofitable.
Growing Profit Margin: 5CV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5CV is unprofitable, and losses have increased over the past 5 years at a rate of 14.2% per year.
Accelerating Growth: Unable to compare 5CV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5CV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 5CV has a negative Return on Equity (-61.15%), as it is currently unprofitable.